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Results In the present work, a relationship was identified 
between RAD51 G135C polymorphism and the incidence 
of endometrial cancer. Endometrial cancer patients had an 
overrepresentation of 135C allele. The 135C/C homozy-
gous variant increased cancer risk. A tendency towards a 
decreased risk of endometrial cancer was observed with 
the occurrence of combined G135C–G172G genotype 
of RAD51 polymorphism. An association was confirmed 
between RAD51 G135C and G172T polymorphisms and 
endometrial cancer progression, assessed by the histologi-
cal grades.
Conclusions The results support the hypothesis that 
RAD51 G135C and G172T polymorphisms may be 
associated with endometrial cancer occurrence and/or 
progression.
Keywords Endometrial cancer · RAD51 · Gene 
polymorphism
Introduction
Endometrial cancer (EC) is the fourth among all malignant 
neoplasms in women, after breast cancer, lung cancer and 
large intestine cancer [1–3].
Prognostic factors (age, hormonal condition, diabetes, 
hypertension, obesity, sterility, low birth number, late men-
opause and genetic factors) commonly used for the identi-
fication of EC present an incomplete picture of the tumor 
biology of endometrial cancer [1]. Therefore, investigation 
of other prognostic factors is of special clinical relevance, 
particularly in view of the unexpectedly progressive course 
of the disease and frequent relapses in some cases.
Double-strand DNA breaks (DSBs) are the most danger-
ous DNA damage [4]. If not repaired, they cause loss of 
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chromosomes and cell death [4]. An accumulation of DSBs 
destabilizes the genome and rearranges it, leading to down-
regulation of transcription and development of various can-
cer diseases [4].
Double-strand DNA breaks are repaired by the follow-
ing two mechanisms: recombination (HR) and non-homol-
ogous end joining (NHEJ) [5].
RAD51 homolog (RecA homolog, Escherichia coli) 
(Saccharomyces cerevisiae) is involved in the homologous 
recombination and repair of double-strand breaks in DNA 
and DNA cross-links, as well as in the maintenance of 
chromosome stability [4].
Literature data suggest that RAD51 levels do not gener-
ally increase in normal cells [6]. Raderschall et al. [7] showed 
that increased levels of RAD51 in tumor cells were found to 
be associated with unscheduled HR and genetic instability. 
Therefore, we suggest that the elevated levels of RAD51 may 
be signalling the presence of extensive DNA damage.
Changes in RAD51 biosynthesis are usually preceded 
by changes in its gene transcription and mRNA level [8]. 
Gene variability could contribute to the level of RAD51 
biosynthesis.
RAD51 gene is highly polymorphic: two common 
RAD51 single nucleotide polymorphisms (SNPs) G135C 
(rs1801320) and G172T (rs1801321) in the 5′UTR have 
been reported to be associated with altered gene transcrip-
tion [9, 10]. It is suggested that these two polymorphisms, 
located at the regulatory locus of RAD51 promoter, are 
associated with mRNA expression [10].
Polymorphisms in DNA repair genes, such as RAD51, 
may alter the activity of the proteins and, thus, modulate 
cancer susceptibility [11–17].
A large number of molecular epidemiologic studies have 
been performed on various neoplasms, such as cancer of 
breast, bladder, lung, head and neck and skin to evaluate 
the role of RAD51 polymorphisms [18–22].
In the literature, many reports confirm that RAD51 
G135C and G172T polymorphisms may be associated with 
the development of certain types of cancers [14, 15, 23–
27], but little is known about their association with endo-
metrial carcinoma.
The study of RAD51 G135C polymorphism in Polish 
population identified a haplotype associated with endome-
trial cancer [28–30]. Romanowicz et al. [28] showed that 
the RAD51 C135C genotype is associated with the risk 
of EC in Polish women. Similar results were obtained by 
Krupa et al. [30] in Polish population. Smolarz et al. [29] 
found the correlation between the RAD51 G135C polymor-
phism and endometrial cancer. The RAD51 135C allele was 
associated with a significantly increased risk of endome-
trial cancer in Poland [30].
A recent study on the Polish populations has provided 
the first epidemiological evidence supporting a connection 
between RAD51 gene variants and the development of 
endometrial premalignant lesions [28–30].
These data prompted us to search for an association 
between EC occurrence and the G135C (rs1801320) and 




A total of 630 patients with histologically proven diagnosis 
of endometrial cancer were included in the reported study. 
The full characteristics of the study group are presented in 
Table 1. Paraffin embedded tumor tissue specimens were 
obtained from postmenopausal women with endometrial 
carcinoma, treated at the Department of Menopausal Dis-
eases, Institute of Polish Mother’s Memorial Hospital 
(Lodz, Poland), between 1998 and 2012. All the diagnosed 
tumors were graded by criteria of the International Federa-
tion of Gynaecology and Obstetrics (FIGO) [31]. Control 
samples consisted of DNA extracted from normal endo-
metrial tissue from age-matched 630 cancer-free women. 
Normal endometrial specimens were obtained from 
patients who had undergone hysterectomy for intramural 
leiomyomas.
DNA isolation
Endometrial tissue samples (cancerous and non-cancerous) 
were routinely fixed in formaldehyde, embedded in par-
affin, cut into thin slices and stained with haematoxylin/
eosin for pathological examination. DNA for analysis was 
obtained from archival pathological paraffin-embedded 
(Department of Pathology, Institute of the Polish Mother’s 
Memorial Hospital, Lodz, Poland) samples, which were 
deparaffinized in xylene and rehydrated in ethanol and dis-
tilled water. In order to ensure that the chosen histological 
material was representative for cancerous and non-cancer-
ous tissue, each sample qualified for DNA extraction was 
initially checked by a pathologist. DNA was extracted from 
the material, using a commercially available QIAmp Kit 
(Qiagen, Hilden, Germany), according to the manufactur-
er’s instruction. The Local Ethics Committee approved the 
study and each patient gave a written consent (No 4/2011).
Genotyping
Single nucleotide polymorphism G135C of RAD51 gene 
was determined by polymerase chain reaction–restriction 
fragment length polymorphism (PCR–RFLP), using the 
following primers: 5′-TGG GAA CTG CAA CTC ATC 
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TGG-3′ (forward) and 5′-GCG CTC CTC TCT CCA GCA 
G-3′ (reverse) [20].
The PCR analysis was carried out in a PTC-100TM 
(MJ Research, INC, Waltham, MA, USA) thermal cycler. 
All PCRs were carried out in a volume of 25 μl, contain-
ing 100 ng of genomic DNA, 0.2 μmol of each appropriate 
primer (ARK Scientific GmbH Biosystems, Darmstadt, 
Germany), 2.5 mM MgCl2, 1 mM dNTPs and 1 U of Taq 
Polymerase (Qiagen GmbH, Hilden, Germany).
RAD51 G135C genotyping was analyzed by PCR ampli-
fication of a 175-bp region around nucleotide 135. That 
region contained a single MvaI site that was abolished in 
the 135C allele. Wild-type alleles were digested by MvaI 
(New England BioLabs, Frankfurt am Main, Germany), 
resulting in 86- and 71-bp products. The 135C allele was 
not digested by the enzyme, resulting in a single 157-bp 
product.
The PCR cycle conditions included 94 °C for 60 s, 54 °C 
for 30 s then 72 °C for 40 s, repeated for 35 cycles. Follow-
ing the digestion with MvaI for 4 h at 37 °C, the samples 
were run on 2 % agarose gel and visualized by ethidium 
bromide staining. Each subject was classified into one of 
the three possible genotypes: 135G/G, 135G/C or 135C/C.
Single nucleotide polymorphism G172T of RAD51 gene 
was analyzed by the PCR–RFLP technique, using the fol-
lowing primers: 5′-TGG GAA CTG CAA CTC ATC TGG-3′ 
(forward) and 5′-GCT CCG ACT TCA CCC CGC CGG-3′ 
(reverse) [21].
The PCR profile for G172T polymorphism consisted of 
an initial melting step at 95 °C for 5 min, followed by 30 
cycles of 95 °C for 30 s, 65 °C for 45 s and 72 °C for 50 s 
plus a final extension step of 72 °C for 10 min. The prod-
uct after PCR was digested with NgoMIV (New England 
BioLabs, Frankfurt am Main, Germany) overnight. The 
products were separated in 2 % agarose gel. The 172G/G 
genotype produced two bands (110 and 21 bp), whereas the 
172T/T genotype produced only one band (131 bp) and the 
172G/T heterozygote displayed all the three bands (131, 
110 and 21 bp).
Statistical analysis
The observed numbers of each RAD51 genotype were 
compared with those expected for a population in Hardy–
Weinberg equilibrium (HWE), using the Chi-square test. 
The genotypic-specific risks were estimated as odds ratios 
(ORs) with associated 95 % intervals (CIs) by uncondi-
tional logistic regression. The wild-type alleles were used 
as reference groups. OR for each combination was calcu-
lated with homozygous wild-type variant combination as 
reference. p values <0.05 were considered significant. All 
the statistical analyses were performed using the STATIS-
TICA 6.0 software (Statsoft, Tulsa, Oklahoma, USA).
Results
All the recruited samples were successfully genotyped for 
RAD51 polymorphisms. After the PCR analysis, all the 
Table 1  Characteristics of the study populations
n = 630




BMI (body mass index) (kg/m2)
 <24.9 120 (19 %)
 25–29.9 222 (35 %)
 >30 288 (46 %)
Number of pregnancies
 1 222 (36 %)
 2–3 408 (64 %)
 >4 0
Use of hormone replacement therapy, HRT
 Yes 432 (69 %)
 No 198 (31 %)
First menarche
 Before 11 years 80 (12 %)
 12–13 years 320 (51 %)
 14–15 years 170 (27 %)
 After 16 years 60 (10 %)
FIGO grade
 G1 180 (29 %)
 G2 420 (67 %)
 G3 30 (5 %)
FIGO stage
 I 174 (28 %)
 II 441 (70 %)




 Yes 450 (71 %)
 No 180 (29 %)
Endometrial transvaginal ultrasound, TVU
 >5 mm 543 (86 %)
Diabetes mellitus
 Yes 186 (30 %)
 No 444 (70 %)
Hypertension
 Yes 360 (57 %)
 No 270 (43 %)
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patients and controls were classified into three genotypes 
of the G135C polymorphism, namely 135G/G, 135G/C 
and 135C/C, and of the G172T polymorphism, namely 
172G/G, 172G/T and 172T/T.
The genotype frequency of the RAD51 G135C and of 
the RAD51 G172T single nucleotide polymorphisms in the 
endometrial cancer samples and controls has been summa-
rized in Table 2.
It can be seen from this Table 2 that there are significant 
differences in the frequency of RAD51 G135C genotypes 
(p < 0.05) between the two investigated groups. A weak 
association was observed between endometrial carcinoma 
occurrence and the presence of 135C/C and 135G/C gen-
otypes. A stronger association was observed for 135C/C 
than for 135G/C heterozygous variant. Variant C allele of 
RAD51 increased cancer risk. That increase was statisti-
cally significant (p < 0.05). In case of the G135C polymor-
phism of RAD51 gene the distribution of the genotypes in 
the patients differed significantly from one expected from 
the Hardy–Weinberg equilibrium (p < 0.05).
No statistically significant differences were observed 
in genotype frequencies of RAD51 G172T polymor-
phism between the control group and the EC patients (see 
Table 3). Among the patients, all genotype distributions did 
not differ significantly (p > 0.05) from those expected by 
the HWE.
A haplotype analysis was performed to estimate the 
interaction between the G135C polymorphism of RAD51 
gene, as well as between the G172T polymorphism of 
RAD51 and endometrial cancer occurrence. The haplotype 
analysis, according to the wild-type of G135G–G172G, 
showed a high incidence of C135C–G172G, C135C–
G172T and C135C–T172T genotypes (see Table 4). The 
combined G135C–G172G genotype decreased the risk of 
endometrial cancer occurrence (p < 0.05).
Histological grading was related to RAD51 G135C and 
G172T polymorphisms. Histological grades were evaluated 
in all the cases (n = 630). There were: G1, 180 cases; G2, 
420 cases and G3, 30 cases. Grades 2 and 3 were accounted 
together for statistical analysis (see Table 5). Some correla-
tion was observed between the RAD51 G135C and G172T 
polymorphisms, and endometrial cancer invasiveness. An 
increase was observed, regarding 135C allele frequency 
(OR 1.43; 95 % CI 1.09–1.88, p = 0.011) and 172T allele 
(OR 3.81; 95 % CI 2.90–5.01, p < 0.0001) in G1 patients, 
according to FIGO classification [31]. That increase 
was statistically significant (p < 0.05). A tendency for an 
increased risk of EC was observed with the occurrence of 
T172T genotype of RAD51 polymorphism (p < 0.05).
We did not find any association of the RAD51 poly-
morphisms in the patients group with cancer progression 
assessed by endometrial cancer staging (p > 0.05) (data not 
shown).
Our data did not demonstrate any statistically signifi-
cant correlation between RAD51 polymorphisms and the 
risk factors for endometrial cancer, such as BMI (body 
mass index), HRT (hormone replacement therapy), uter-
ine bleeding, endometrial transvaginal ultrasound, diabetes 
Table 2  The allele and genotype frequency and odds ratio (OR) of G135C polymorphism of the RAD51 gene in endometrial cancer and controls
Data in boldface are statistically significant
a
 Crude odds ratio (OR); 95 % CI, confidence interval at 95 %
b
 Chi-square
RAD51 G135C Patients (n = 630) Controls (n = 630) OR (95 % CI)a pb
Number (%) Number (%)
G/G 129 20 189 30 1.00 Ref
G/C 135 22 297 47 0.66 (0.49–0.90) 0.010
C/C 366 58 144 23 3.72 (2.77–5.00) <0.0001
G 393 31 675 54 1.00 Ref
C 867 69 585 46 2.54 (2.16–2.99) <0.0001
Table 3  The allele and 
genotype frequency and 
odds ratio (OR) of G172T 
polymorphism of the RAD51 
gene in endometrial cancer and 
controls
a
 Crude odds ratio (OR); 95 % 
CI, confidence interval at 95 %
b
 Chi-square
RAD51 G172T Patients (n = 630) Controls (n = 630) OR (95 % CI)a pb
Number (%) Number (%)
G/G 159 25 177 28 1.00 Ref
G/T 276 44 264 42 1.16 (0.88–1.52) 0.307
T/T 195 31 189 30 1.14 (0.85–1.53) 0.392
G 594 47 618 49 1.00 Ref
T 666 53 642 51 1.07 (0.92–1.26) 0.359
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and hypertension and women with endometrial cancer, here 
again erase the remark “(data not shown)”.
Discussion
In the presented study, the role of polymorphisms was stud-
ied in DNA DSB repair RAD51 gene, the polymorphisms 
being regarded as risk factors for endometrial cancer in 
a case setting. The following SNPs were considered in 
the homologous recombination (HRR) pathway: RAD51 
G135C and G172T.
Homologous recombinational repair plays a critical role 
in repairing DNA damage [4, 5, 32]. The RAD51 protein 
is a core component of DNA double-strand break repair by 
HRR [9].
The cells, which are deficient in this gene product, are 
defective in homologous recombination and demonstrate 
genomic instability [9].
The cellular reaction to DNA damaging agents can mod-
ulate the susceptibility towards tumor development [33]. 
This reaction is mainly determined by the efficacy of DNA 
repair, which may, in turn, be influenced by the variability 
of DNA repair genes, expressed by their polymorphisms 
[34–37].
The variability of RAD51 repair gene could contribute to 
the protein biosynthesis level [38–40].
It is supposed that the polymorphism of the RAD51 gene 
has been associated with interindividual differences in the 
basal steady state level of its protein [9, 10]. The RAD51 
gene has been mapped to 15q14-15 chromosome and is 
highly polymorphic in nature [9, 10].
As mentioned in the “Introduction” above, the involve-
ment of RAD51 in DNA repair determines its potential role 
in maintaining the genomic stability, which is disturbed in 
various malignancies [11–17]. Therefore, the problem of 
genetic variability of the RAD51 gene for tumor develop-
ment is worth to be studied.
A G to C substitution at position 135 and G to T substi-
tution at position 172 of the RAD51 gene (5′-untranslated 
region) have been described as single nucleotide polymor-
phisms (SNPs) [8]. Both polymorphisms are located in the 
regulatory element of the RAD51 promoter and are sug-
gested to be associated with messenger RNA stability and 
expression [9, 10].
Table 4  Frequency of the RAD51 haplotypes among endometrial cancer patients and control subjects
Data in boldface are statistically significant
a
 Crude odds ratio (OR); 95 % CI, confidence interval at 95 %
b
 Chi-square
Haplotypes RAD51-135–172 Patients (n = 630) N (%) Controls (n = 630) N (%) OR (95 % CI)a pb
G/G–G/G 45 (7.1) 75 (11.9) 1.00 Ref.
G/G–G/T 48 (7.6) 51 (8.1) 1.56 (0.91–2.69) 0.134
G/G–T/T 45 (7.1) 60 (9.5) 1.25 (0.73–2.13) 0.492
G/C–G/G 20 (8.1) 72 (11.7) 0.46 (0.24–0.85) 0.020
G/C–G/T 45 (7.1) 114 (11.4) 0.66 (0.39–1.09) 0.134
G/C–T/T 45 (7.1) 75 (11.9) 1.00 (0.59–1.68) 0.887
C/C–G/G 120 (14.3) 57 (9.0) 3.50 (2.15–5.70) <0.0001
C/C–G/T 165 (26.2) 69 (10.9) 3.98 (2.50–6.34) <0.0001
C/C–T/T 96 (15.2) 57 (9.0) 2.81 (1.71–4.60) <0.0001
Table 5  Dependence of genotypes and frequencies of RAD51 gene 
polymorphism alleles on tumor grade in endometrial cancer patients
Data in boldface are statistically significant
n = 630
a
 According to FIGO criteria
b
 Crude odds ratio (OR); 95 % CI, confidence interval at 95 %
c
 Chi-square
Gradea Endometrial cancer patients OR (95 % CI)b pc
G1 
(n = 180)
G2 + G3 
(n = 450)
Number (%) Number (%)
RAD51 G135C
 G/G 29 (16) 100 (22) 1.00 Ref
 G/C 35 (20) 100 (22) 1.21 (0.68–2.12) 0.610
 C/C 116 (64) 250 (56) 1.60 (1.00–2.55) 0.062
 G 93 (26) 300 (33) 1.00 Ref
 C 267 (74) 600 (67) 1.43 (1.09–1.88) 0.011
RAD51 G172T
 G/G 20 (11) 139 (31) 1.00 Ref
 G/T 50 (28) 226 (50) 1.53 (0.87–2.69) 0.168
 T/T 110 (61) 85 (19) 8.99 (5.20–15.55) <0.0001
 G 90 (25) 504 (56) 1.00 Ref
 T 270 (75) 396 (44) 3.81 (2.90–5.01) <0.0001
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The results of several previous studies suggest that 
RAD51 plays an important role in repair of double-strand 
breaks in DNA [33, 41]. Defects of genes, involved in DSB 
repair, often lead to better cancer development [33].
The RAD51 polymorphisms were found to be associated 
with various cancer diseases [12, 17, 42, 43] but little data are 
available on the association or its lack in endometrial cancer.
According to several research endeavors described in 
the current literature, polymorphisms in the 5′ untranslated 
region of RAD51 gene may contribute to endometrial car-
cinogenesis [28–30].
Recent reports introduce the role of G135C polymor-
phism in the development of endometrial cancer [28, 30].
However, the study was carried out on a relatively small 
patient population, thus the obtained results cannot be con-
sidered as definitive and require further, more extensive 
evaluations, performed on bigger groups of patients.
In view of the potentially significant role of the DNA 
repair machinery for more intensive cancer development, 
it is important to know whether the RAD51 gene polymor-
phism can account for the appearance of endometrial can-
cer occurrence. Therefore, we analyzed the role of G135C 
and G172T genetic variations in the homologous recombi-
nation repair gene and for the risk of developing EC.
In the presented study, the PCR–RFLP technique was 
used to screen 630 endometrial cancer patients for RAD51 
polymorphisms.
A significant difference was found in the incidence of 
allele distribution among investigated samples. In the pre-
sented study, the incidence of 135C allele in the examined 
patients was higher than that of 135C allele in control sam-
ples (69 vs. 46 %, respectively). The genotype distribution 
in the patients differed from that, expected from the Hardy–
Weinberg equilibrium, with an overrepresentation of 135C 
allele. Moreover, 135C/C genotype increased the risk of 
EC. It is possible that the presence of C allele remains in 
some linkage disequilibrium with another, so far unknown, 
mutation, located outside of the coding region in the RAD51 
gene, which may be of importance for the RAD51 concen-
tration in plasma and more severe cancer development.
On the other hand, no significant difference was found 
among the G172T genotypes in tumor and normal endome-
trial tissues. We realize that this may have been due to the 
rather small population enrolled into the study or due to de 
novo mutations in investigated samples.
In the reported study, the G135C polymorphism of 
RAD51 gene and G172T of RAD51, were correlated with 
endometrial carcinoma progression. 135C and 172T alleles 
were associated with an increased risk of grade 1 endome-
trial cancer.
In conclusion, the reported study is another evidence 
for the significance of G135C and G172T genotypes in EC 
grading.
Thus we conclude that our observations may be an 
important signal, prompting to appreciate the role of 
RAD51 in EC development and likely triggering further 
studies on this interesting subject.
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